

Quanex Building Products Announces Fourth Quarter and Full Year 2023 Results

Another Record Quarter for Earnings

Margin Expansion Across All Operating Segments
Repaid \$40 Million in Bank Debt in Quarter
Balance Sheet and Liquidity Remain Strong
Record Year for Cash Provided by Operating Activities

HOUSTON, TEXAS – December 14, 2023 - Quanex Building Products Corporation (NYSE:NX) ("Quanex" or the "Company") today announced its results for the three months and twelve months ended October 31, 2023.

The Company reported the following selected financial results:

	Three Months Er	nded October 31,	Twelve Months Ended October 31,			
(\$ in millions, except per share data)	2023	2022	2023	2022		
Net Sales	\$295.5	\$307.5	\$1,130.6	\$1,221.5		
Gross Margin	\$80.0	\$67.5	\$277.5	\$268.5		
Gross Margin %	27.1%	21.9%	24.5%	22.0%		
Net Income	\$27.4	\$24.7	\$82.5	\$88.3		
Diluted EPS	\$0.83	\$0.75	\$2.50	\$2.66		
Adjusted Net Income	\$31.2	\$25.0	\$90.9	\$88.9		
Adjusted Diluted EPS	\$0.95	\$0.75	\$2.75	\$2.68		
Adjusted EBITDA	\$50.8	\$38.7	\$159.6	\$152.5		
Adjusted EBITDA Margin %	17.2%	12.6%	14.1%	12.5%		
Cash Provided by Operating Activities	\$44.5	\$48.1	\$147.1	\$98.0		
Free Cash Flow	\$29.6	\$34.5	\$109.7	\$64.8		

(See Non-GAAP Terminology Definitions and Disclaimers section, Non-GAAP Financial Measure Disclosure table, Selected Segment Data table and reconciliation tables for additional information)

George Wilson, President and Chief Executive Officer, commented, "We reported another record quarter for earnings and our balance sheet and liquidity remain strong. Despite pressure on revenue due to market volume softness related to ongoing macroeconomic challenges, and some pricing pressure as raw material costs declined, we converted very well and realized margin expansion across all operating segments in both the fourth quarter and the full year. Our continued focus on controlling what we can control helped drive our improved results and we believe we are hitting our stride from an operational standpoint. Overall, we are proud of what we were able to accomplish in 2023.

"Managing working capital and generating cash is a core focus of ours, which enabled us to pay down our bank debt by \$40 million during the fourth quarter alone. In fact, we generated record free cash flow in 2023." (See Non-GAAP Terminology Definitions and Disclaimers section and Free Cash Flow reconciliation table for additional information)

Fourth Quarter and Fiscal 2023 Results Summary

Quanex reported net sales of \$295.5 million during the three months ended October 31, 2023, which represents a decrease of 3.9% compared to \$307.5 million for the same period of 2022. The Company reported net sales of \$1.13 billion during the twelve months ended October 31, 2023, which represents a decrease of 7.4% compared to \$1.22 billion for the same period of 2022. The decreases were primarily attributable to softer market demand and lower pricing in North America. Quanex reported net sales growth of 1.3% for the fourth quarter of 2023 and a decline of 2.9% in net sales for the full year in its North American Fenestration segment. Excluding the contribution from the LMI Custom Mixing assets the Company acquired on November 1, 2022, net sales in the North American Fenestration segment would have declined by 10.7% for the fourth quarter and 13.9% for the full year. In its North American Cabinet Components segment, Quanex reported a decline of 23.7% in net sales for the fourth quarter and a decline of 21.9% in net sales for the full year. Excluding foreign exchange impact, the Company realized a decrease in net sales of 3.7% for the fourth quarter and a decrease of 2.8% in net sales for the full year in its European Fenestration segment. (See Sales Analysis table for additional information)

The increase in adjusted earnings for the three months and twelve months ended October 31, 2023 was largely attributable to effective cost control, real price increases, a decline in raw material costs and a decrease in income tax expense. As such, Quanex was able to realize margin expansion in the fourth quarter and full year in each of its operating segments and on a consolidated basis.

Balance Sheet Update

As of October 31, 2023, Quanex had total debt of \$70.0 million (\$18.5 million excluding real-estate leases that are considered "finance" leases under U.S. GAAP) and the Company's leverage ratio of Net Debt to LTM Adjusted EBITDA decreased to 0.1x (Net Debt free excluding these real-estate leases). As of October 31, 2023, Quanex's LTM Adjusted EBITDA was \$159.6 million and LTM Net Income, the most directly comparable GAAP measure, was \$82.5 million. (See Non-GAAP Terminology Definitions and Disclaimers section, Net Debt Reconciliation table and Last Twelve Months Adjusted EBITDA Reconciliation table for additional information)

Outlook

Mr. Wilson stated, "We enter fiscal 2024 with a somewhat cautious outlook for the first half due to the ongoing macroeconomic challenges combined with typical seasonality in our business, but we are optimistic that demand for our products will improve in the second half as consumer confidence is restored over time. However, consistent with the last two years, based on current macro indicators, recent conversations with our customers, limited transparency, and varying opinions on the outlook for 2024, we are taking a thoughtful approach to guidance for 2024. As such, we believe it would be premature to give guidance at this time and intend to re-visit guidance for 2024 when we report earnings for the first quarter. Our long-term view continues to be optimistic as the underlying fundamentals for the residential housing market remain positive."

Conference Call and Webcast Information

The Company has also scheduled a conference call for Friday, December 15, 2023 at 11:00 a.m. ET (10:00 a.m. CT) to discuss the release. A link to the live audio webcast will be available on Quanex's website at http://www.quanex.com in the Investors section under Presentations & Events.

Participants can pre-register for the conference call using the following link: https://register.vevent.com/register/BI8c21998a92f24071bb721ad032dd7661

Registered participants will receive an email containing conference call details for dial-in options. To avoid delays, it is recommended that participants dial into the conference call ten minutes ahead of the scheduled start time. A replay will be available for a limited time on the Company's website at http://www.guanex.com in the Investors section under Presentations & Events.

About Quanex

Quanex is a global manufacturer with core capabilities and broad applications across various end markets. The Company currently collaborates and partners with leading OEMs to provide innovative solutions in the window, door, vinyl fencing, solar, refrigeration, custom mixing and cabinetry markets. Looking ahead, Quanex plans to leverage its material science expertise and process engineering to expand into adjacent markets.

For more information contact Scott Zuehlke, Senior Vice President, Chief Financial Officer & Treasurer, at 713-877-5327 or scott.zuehlke@quanex.com.

Non-GAAP Terminology Definitions and Disclaimers

Adjusted Net Income (defined as net income further adjusted to exclude purchase price accounting inventory step-ups, transaction costs, certain severance charges, gain/loss on the sale of certain fixed assets, restructuring charges, asset impairment charges, other net adjustments related to foreign currency transaction gain/loss and effective tax rates reflecting impacts of adjustments on a with and without basis) and Adjusted EPS are non-GAAP financial measures that Quanex believes provide a consistent basis for comparison between periods and more accurately reflects operational performance, as they are not influenced by certain income or expense items not affecting ongoing operations. EBITDA (defined as net income or loss before interest, taxes, depreciation and amortization and other, net) and Adjusted EBITDA (defined as EBITDA further adjusted to exclude purchase price accounting inventory step-ups, transaction costs, certain severance charges, gain/loss on the sale of certain fixed assets, restructuring charges and asset impairment charges) are non-GAAP financial measures that the Company uses to measure operational performance and assist with financial decision-making. Net Debt is defined as total debt (outstanding balance on the revolving credit facility plus financial lease obligations) less cash and cash equivalents. The leverage ratio of Net Debt to LTM Adjusted EBITDA is a financial measure that the Company believes is useful to investors and financial analysts in evaluating Quanex's leverage. In addition, with certain limited adjustments, this leverage ratio is the basis for a key covenant in the Company's credit agreement.

Free Cash Flow is a non-GAAP measure calculated using cash provided by operating activities less capital expenditures. Quanex uses the Free Cash Flow metric to measure operational and cash management performance and assist with financial decision-making. Free Cash Flow is measured before application of certain contractual commitments (including capital lease obligations), and accordingly is not a true

measure of the Company's residual cash flow available for discretionary expenditures. Quanex believes Free Cash Flow is useful to investors in understanding and evaluating the Company's financial and cash management performance.

Quanex believes that the presented non-GAAP measures provide a consistent basis for comparison between periods and will assist investors in understanding the Company's financial performance when comparing results to other investment opportunities. The presented non-GAAP measures may not be the same as those used by other companies. Quanex does not intend for this information to be considered in isolation or as a substitute for other measures prepared in accordance with U.S. GAAP.

Forward Looking Statements

Statements that use the words "estimated," "expect," "could," "should," "believe," "will," "might," or similar words reflecting future expectations or beliefs are forward-looking statements. The forward-looking statements include, but are not limited to, the following: impacts from public health issues (including pandemics, such as the recent COVID-19 pandemic) on the economy and the demand for Quanex's products, the Company's future operating results, future financial condition, future uses of cash and other expenditures, expenses and tax rates, expectations relating to Quanex's industry, and the Company's future growth, including any guidance discussed in this press release. The statements and guidance set forth in this release are based on current expectations. Actual results or events may differ materially from this release. For a complete discussion of factors that may affect Quanex's future performance, please refer to the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2022, and the Company's Quarterly Reports on Form 10-Q under the sections entitled "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors". Any forward-looking statements in this press release are made as of the date hereof, and Quanex undertakes no obligation to update or revise any forward-looking statements to reflect new information or events.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data) (Unaudited)

	Thr	ee Months En	ided Oc	October 31, Twelve Months Er			Ended (nded October, 31		
		2023		2022		2023		2022		
Net sales	\$	295,492	\$	307,532	\$	1,130,583	\$	1,221,502		
Cost of sales		215,473		240,073		853,059		953,004		
Selling, general and administrative		29,326		29,334		123,957		117,108		
Depreciation and amortization		11,194		9,555		42,866		40,109		
Operating income		39,499		28,570		110,701		111,281		
Interest expense		(1,565)		(710)		(8,136)		(2,559)		
Other, net		(6,110)		136		(5,519)		1,041		
Income before income taxes		31,824		27,996		97,046		109,763		
Income tax expense		(4,442)		(3,329)		(14,545)		(21,427)		
Netincome	\$	27,382	\$	24,667	\$	82,501	\$	88,336		
Earnings per common share, basic	\$	0.84	\$	0.75	\$	2.51	\$	2.67		
Earnings per common share, diluted	\$	0.83	\$	0.75	\$	2.50	\$	2.66		
Weighted average common shares outstanding:										
Basic		32,753		32,916		32,819		33,048		
Diluted		32,991		33,082		33,026		33,205		
Cash dividends per share	\$	0.08	\$	0.08	\$	0.32	\$	0.32		

QUANEX BUILDING PRODUCTS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands) (Unaudited)

	Octob	per 31, 2023	October 31, 2022		
ASSETS		_			
Current assets:					
Cash and cash equivalents	\$	58,474	\$	55,093	
Accounts receivable, net		97,311		96,018	
Inventories, net		97,959		120,890	
Income taxes receivable		8,298		-	
Prepaid and other current assets		11,558		8,664	
Total current assets		273,600		280,665	
Property, plant and equipment, net		250,664		180,400	
Operating lease right-of-use assets		46,620		56,000	
Goodwill		182,956		137,855	
Intangible assets, net		74,115		65,035	
Other assets		3,188		4,662	
Total assets	\$	831,143	\$	724,617	
LIABILITIES AND STOCKHOLDERS' EQUITY					
Current liabilities:					
Accounts payable	\$	74,371	\$	77,907	
Accrued liabilities		50,319		52,114	
Income taxes payable		384		1,049	
Current maturities of long-term debt		2,365		1,046	
Current operating lease liabilities		7,224		7,727	
Total current liabilities		134,663		139,843	
Long-term debt		66,435		29,628	
Noncurrent operating lease liabilities		40,361		49,286	
Deferred pension benefits		-		3,917	
Deferred income taxes		29,133		22,277	
Liabilities for uncertain tax positions		250		1,361	
Other liabilities		14,747		13,470	
Total liabilities		285,589		259,782	
Stockholders' equity:					
Common stock		372		372	
Additional paid-in-capital		251,576		251,947	
Retained earnings		409,318		337,456	
Accumulated other comprehensive loss		(38,141)		(49,422)	
Treasury stock at cost		(77,571)		(75,518)	
Total stockholders' equity		545,554		464,835	
Total liabilities and stockholders' equity	\$	831,143	\$	724,617	

QUANEX BUILDING PRODUCTS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(In thousands) (Unaudited)

Operating activities: 2023 2022 Net income \$ 82,501 \$88,336 Adjustments to reconcile net income to cash provided by operating activities: Secondary 100 \$80,300 Depreciation and amortization 42,866 40,109 Loss on the disposition of capital assets 278 109 Stock-based compensation 5,147 2,097 Other, net 1,529 1,905 Changes in assets and liabilities: 6,969 6,945 Decrease in accounts receivable 6,969 6,945 Decrease (increase) in inventory 30,024 (32,035) Increase in other current assets (1,880) (970) Decrease in income taxes payable (11,611) (3,047) Decrease in income taxes payable (9,009) (5,192) (Decrease in intome taxes payable (9,009) (5,192) (Decrease in other long-term liabilities 683 305 Other, net (3,39) 3,312 Cash provided by operating activities (3,39) (3,192) Investing activities (37,30)		Twe	elve Months E	nded O	ctober, 31	
Net income \$ 82,501 \$ 88,336 Adjustments to reconcile net income to cash provided by operating activities: 32,866 40,109 Depreciation and amortization 42,866 40,109 Loss on the disposition of capital assets 278 109 Stock-based compensation 2,521 2,291 Deferred income tax 5,147 2,097 Other, net 1,529 1,905 Changes in assets and liabilities: 6,969 6,945 Decrease in accounts receivable 6,969 6,945 Decrease in incornet creeivable 6,969 6,945 Decrease in incornet secivable (1,680) (970) Decrease in accounts payable (11,611) (3,047) Decrease in income taxes payable (9,009) (5,192) (Decrease) increase in deferred pension benefits 3359 77 Increase in other long-term liabilities (83 305 Other, net (16 (1,642) 194 Cash provided by operating activities (9,009) (5,192 Investing activities (9,009) <th></th> <th>-</th> <th></th> <th colspan="3"></th>		-				
Adjustments to reconcile net income to cash provided by operating activities: 42,866 40,109 Depreciation and amortization 42,866 40,109 Loss on the disposition of capital assets 278 109 Stock-based compensation 2,521 2,291 Deferred income tax 5,147 2,097 Other, net 1,529 1,905 Changes in assets and liabilities: 8,969 6,945 Decrease in accounts receivable 6,969 6,945 Decrease in inctrease in interverrent assets (1,880) (970) Decrease in accounts payable (11,611) (3,047) Decrease in accrued liabilities (4,249) (3,159) Decrease in increase in deferred pension benefits (359) 77 Increase in other long-term liabilities 683 305 Other, net 1,642 194 Cash provided by operating activities 147,052 97,965 Investing activities: 31,052 19,002 1 Envesting activities 32,303 (33,130) (33,121) Proceeds fro	Operating activities:					
Depreciation and amortization 42,866 40,109 Loss on the disposition of capital assets 278 109 Stock-based compensation 2,521 2,291 Deferred income tax 5,147 2,097 Other, net 1,529 1,905 Changes in assets and liabilities:		\$	82,501	\$	88,336	
Depreciation and amortization 42,866 40,109 Loss on the disposition of capital assets 278 109 Stock-based compensation 2,521 2,291 Deferred income tax 5,147 2,097 Other, net 1,529 1,905 Changes in assets and liabilities: 8,969 6,945 Decrease in accounts receivable 6,969 6,945 Decrease (increase) in inventory 30,024 (32,035) Increase in other current assets (1,880) (970) Decrease in accounts payable (11,611) (3,047) Decrease in income taxes payable (9,009) (5,192) (Decrease) increase in deferred pension benefits (359) 77 Increase in other long-term liabilities 683 305 Other, net 1,642 194 Cash provided by operating activities (37,390) (33,121) Investing activities (37,390) (33,121) Proceeds from disposition of capital assets 253 159 Cash used for investing activities 102,000 70,500						
Loss on the disposition of capital assets 278 109 Stock-based compensation 2,521 2,291 Deferred income tax 5,147 2,097 Other, net 1,529 1,905 Changes in assets and liabilities: 3,699 6,945 Decrease in accounts receivable 6,969 6,945 Decrease in accounts receivable 1,880 (970) Increase in other current assets 1,880 (970) Decrease in accounts payable (11,611) (3,047) Decrease in accrued liabilities (4,249) (3,159) Decrease in income taxes payable (9,009) (5,192) (Decrease) increase in deferred pension benefits (359) 77 Increase in other long-term liabilities 683 305 Other, net 1,642 194 Cash provided by operating activities (359) 77 Increase in other long-term liabilities (91,302) - Capital expenditures (37,390) (33,121) Proceeds from disposition of capital assets 253 159						
Stock-based compensation 2,521 2,291 Deferred income tax 5,147 2,097 Other, net 1,529 1,905 Changes in assets and liabilities: Pecrease in accounts receivable 6,969 6,945 Decrease in accounts receivable 6,969 6,945 Decrease in accounts payable (1,880) (970) Decrease in accounts payable (11,611) (3,047) Decrease in accounts payable (11,611) (3,047) Decrease in accrued liabilities (4,249) (3,159) Decrease in income taxes payable (9,009) (5,192) (Decrease) increase in deferred pension benefits (359) 77 Increase in other long-term liabilities 683 305 Other, net 1,642 194 Cash provided by operating activities 147,052 97,965 Investing activities (91,302) - Business acquisition (91,302) - Capital expenditures (37,390) (33,121) Proceeds from disposition of capital assets 253	•		•		· ·	
Deferred income tax 5,147 2,097 Other, net 1,529 1,905 Changes in assets and liabilities:					109	
Other, net 1,529 1,905 Changes in assets and liabilities: 3 Decrease in accounts receivable 6,969 6,945 Decrease (increase) in inventory 30,024 (32,035) Increase in other current assets (1,880) (970) Decrease in accounts payable (11,611) (3,047) Decrease in accrued liabilities (4,249) (3,159) Decrease in income taxes payable (9,009) (5,192) (Decrease) increase in deferred pension benefits (359) 77 Increase in other long-term liabilities 683 305 Other, net 1,642 194 Cash provided by operating activities 147,052 97,965 Investing activities (91,302) - Capital expenditures (128,439) (32,962) Financing activities (128,439)	·		2,521		2,291	
Changes in assets and liabilities: 6,969 6,945 Decrease (increase) in inventory 30,024 (32,035) Increase in other current assets (1,880) (970) Decrease in accounts payable (11,611) (3,047) Decrease in accound liabilities (4,249) (3,159) Decrease in income taxes payable (9,009) (5,192) (Decrease) increase in deferred pension benefits (359) 77 Increase in other long-term liabilities 683 305 Other, net 1,642 194 Cash provided by operating activities 147,052 97,965 Investing activities: (91,302) - Capital expenditures (37,390) (33,121) Proceeds from disposition of capital assets 253 159 Cash used for investing activities (128,439) (32,962) Financing activities: 253 159 Borrowings under credit facilities 102,000 70,500 Repayments of credit facilities 102,000 70,500 Repayments of credit facilities (2,567)	Deferred income tax		5,147		2,097	
Decrease in accounts receivable 6,969 6,945 Decrease (increase) in inventory 30,024 (32,035) Increase in other current assets (1,880) (970) Decrease in accounts payable (11,611) (3,047) Decrease in accound liabilities (4,249) (3,159) Decrease in income taxes payable (9,009) (5,192) (Decrease) increase in deferred pension benefits (359) 77 Increase in other long-term liabilities 683 305 Other, net 1,642 194 Cash provided by operating activities 147,052 97,965 Investing activities: (91,302) - Capital expenditures (37,390) (33,121) Proceeds from disposition of capital assets 253 159 Cash used for investing activities (128,439) (32,962) Financing activities 102,000 70,500 Repayments of credit facilities 102,000 70,500 Repayments of credit facility borrowings (100,000) (95,500) Debt issuance costs -	Other, net		1,529		1,905	
Decrease (increase) in inventory 30,024 (32,035) Increase in other current assets (1,880) (970) Decrease in accounts payable (11,611) (3,047) Decrease in accrued liabilities (4,249) (3,159) Decrease in income taxes payable (9,009) (5,192) (Decrease) increase in deferred pension benefits (359) 77 Increase in other long-term liabilities 683 305 Other, net 1,642 194 Cash provided by operating activities 147,052 97,965 Investing activities: 337,390 (33,121) Proceeds from disposition of capital assets 253 159 Cash used for investing activities (23,439) (32,962) Financing activities: 253 159 Borrowings under credit facilities 102,000 70,500 Repayments of credit facility borrowings (10,000) (95,500) Debt issuance costs - (1,210) Repayments of other long-term debt (2,567) (1,747) Common stock dividends paid (10,6	Changes in assets and liabilities:					
Increase in other current assets (1,880) (970) Decrease in accounts payable (11,611) (3,047) Decrease in accrued liabilities (4,249) (3,159) Decrease in income taxes payable (9,009) (5,192) (Decrease) increase in deferred pension benefits (359) 77 Increase in other long-term liabilities 683 305 Other, net 1,642 194 Cash provided by operating activities 147,052 97,965 Investing activities: 1 1,642 194 Cash provided by operating activities (91,302) - Capital expenditures (37,390) (33,121) Proceeds from disposition of capital assets 253 159 Cash used for investing activities (128,439) (32,962) Financing activities: 102,000 70,500 Repayments of credit facilities 102,000 70,500 Repayments of other long-term debt (2,567) (1,747) Common stock dividends paid (10,639) (10,598) Issuance of common stock	Decrease in accounts receivable		6,969		6,945	
Decrease in accounts payable (11,611) (3,047) Decrease in accrued liabilities (4,249) (3,159) Decrease in income taxes payable (9,009) (5,192) (Decrease) increase in deferred pension benefits (359) 77 Increase in other long-term liabilities 683 305 Other, net 1,642 194 Cash provided by operating activities 147,052 97,965 Investing activities: 147,052 97,965 Investing activities: (91,302) - Capital expenditures (37,390) (33,121) Proceeds from disposition of capital assets 253 159 Cash used for investing activities (128,439) (32,962) Financing activities: 102,000 70,500 Repayments of credit facilities 102,000 70,500 Repayments of credit facility borrowings (100,000) (95,500) Debt issuance costs - (1,210) Repayments of other long-term debt (2,567) (1,747) Common stock dividends paid (10,639) <td< td=""><td>Decrease (increase) in inventory</td><td></td><td>30,024</td><td></td><td>(32,035)</td></td<>	Decrease (increase) in inventory		30,024		(32,035)	
Decrease in accrued liabilities (4,249) (3,159) Decrease in income taxes payable (9,009) (5,192) (Decrease) increase in deferred pension benefits (359) 77 Increase in other long-term liabilities 683 305 Other, net 1,642 194 Cash provided by operating activities 147,052 97,965 Investing activities: 8 147,052 97,965 Investing activities: 91,302) - - Capital expenditures (91,302) - - Capital expenditures 37,390 (33,121) - Proceeds from disposition of capital assets 253 159 Cash used for investing activities (128,439) (32,962) Financing activities 102,000 70,500 Repayments of credit facilities 102,000 70,500 Repayments of credit facility borrowings (100,000) (95,500) Debt issuance costs - (1,210) Repayments of other long-term debt (2,567) (1,747) Common stock	Increase in other current assets		(1,880)		(970)	
Decrease in income taxes payable (Decrease) increase in deferred pension benefits (Decrease) increase in deferred pension benefits (Decrease) increase in deferred pension benefits (Decrease) increase in other long-term liabilities (Decrease)	Decrease in accounts payable		(11,611)		(3,047)	
(Decrease) increase in deferred pension benefits (359) 77 Increase in other long-term liabilities 683 305 Other, net 1,642 194 Cash provided by operating activities 147,052 97,965 Investing activities: 3147,052 97,965 Investing activities: 31,202 - Business acquisition (91,302) - Capital expenditures (37,390) (33,121) Proceeds from disposition of capital assets 253 159 Cash used for investing activities (128,439) (32,962) Financing activities: 3159 32,962) Borrowings under credit facilities 102,000 70,500 Repayments of credit facility borrowings (100,000) (95,500) Debt issuance costs - (1,210) Repayments of other long-term debt (2,567) (1,747) Common stock dividends paid (10,639) (10,598) Issuance of common stock 1,215 689 Payroll tax paid to settle shares forfeited upon vesting of stock (567)	Decrease in accrued liabilities		(4,249)		(3,159)	
Increase in other long-term liabilities 683 305 Other, net 1,642 194 Cash provided by operating activities 147,052 97,965 Investing activities: 305 147,052 97,965 Investing activities: 305 305 305 305 Capital expenditures (91,302) -	Decrease in income taxes payable		(9,009)		(5,192)	
Other, net 1,642 194 Cash provided by operating activities 147,052 97,965 Investing activities: 8 Usiness acquisition (91,302) - Capital expenditures (37,390) (33,121) Proceeds from disposition of capital assets 253 159 Cash used for investing activities (128,439) (32,962) Financing activities: 8 102,000 70,500 Repayments of credit facilities 102,000 70,500 Repayments of credit facility borrowings (100,000) (95,500) Debt issuance costs - (1,210) Repayments of other long-term debt (2,567) (1,747) Common stock dividends paid (10,639) (10,598) Issuance of common stock 1,215 689 Payroll tax paid to settle shares forfeited upon vesting of stock (567) (1,413) Purchase of treasury stock (5,593) (6,600) Cash used for financing activities (16,151) (45,879) Effect of exchange rate changes on cash and cash equivalents 919 (4,092)	(Decrease) increase in deferred pension benefits		(359)		77	
Cash provided by operating activities Investing activities: Business acquisition (91,302) - Capital expenditures (37,390) (33,121) Proceeds from disposition of capital assets 253 159 Cash used for investing activities (128,439) (32,962) Financing activities: Borrowings under credit facilities 102,000 70,500 Repayments of credit facility borrowings (100,000) (95,500) Debt issuance costs - (1,210) Repayments of other long-term debt (2,567) (1,747) Common stock dividends paid (10,639) (10,598) Issuance of common stock 1,215 689 Payroll tax paid to settle shares forfeited upon vesting of stock (567) (1,413) Purchase of treasury stock (5,593) (6,600) Cash used for financing activities (16,151) (45,879) Effect of exchange rate changes on cash and cash equivalents 919 (4,092) Increase in cash and cash equivalents at beginning of period 55,093 40,061	Increase in other long-term liabilities		683		305	
Investing activities: Business acquisition (91,302) - Capital expenditures (37,390) (33,121) Proceeds from disposition of capital assets 253 159 Cash used for investing activities (128,439) (32,962) Financing activities: Borrowings under credit facilities 102,000 70,500 Repayments of credit facility borrowings (100,000) (95,500) Debt issuance costs - (1,210) Repayments of other long-term debt (2,567) (1,747) Common stock dividends paid (10,639) (10,598) Issuance of common stock 1,215 689 Payroll tax paid to settle shares forfeited upon vesting of stock (567) (1,413) Purchase of treasury stock (5,593) (6,600) Cash used for financing activities (16,151) (45,879) Effect of exchange rate changes on cash and cash equivalents 919 (4,092) Increase in cash and cash equivalents 3,381 15,032 Cash and cash equivalents at beginning of period 55,093	Other, net		1,642		194	
Business acquisition (91,302) - Capital expenditures (37,390) (33,121) Proceeds from disposition of capital assets 253 159 Cash used for investing activities (128,439) (32,962) Financing activities: 8 102,000 70,500 Repayments of credit facility borrowings (100,000) (95,500) Debt issuance costs - (1,210) Repayments of other long-term debt (2,567) (1,747) Common stock dividends paid (10,639) (10,598) Issuance of common stock 1,215 689 Payroll tax paid to settle shares forfeited upon vesting of stock (567) (1,413) Purchase of treasury stock (5,593) (6,600) Cash used for financing activities (16,151) (45,879) Effect of exchange rate changes on cash and cash equivalents 919 (4,092) Increase in cash and cash equivalents 3,381 15,032 Cash and cash equivalents at beginning of period 55,093 40,061	Cash provided by operating activities		147,052		97,965	
Capital expenditures(37,390)(33,121)Proceeds from disposition of capital assets253159Cash used for investing activities(128,439)(32,962)Financing activities:Borrowings under credit facilities102,00070,500Repayments of credit facility borrowings(100,000)(95,500)Debt issuance costs-(1,210)Repayments of other long-term debt(2,567)(1,747)Common stock dividends paid(10,639)(10,598)Issuance of common stock1,215689Payroll tax paid to settle shares forfeited upon vesting of stock(567)(1,413)Purchase of treasury stock(5,593)(6,600)Cash used for financing activities(16,151)(45,879)Effect of exchange rate changes on cash and cash equivalents919(4,092)Increase in cash and cash equivalents3,38115,032Cash and cash equivalents at beginning of period55,09340,061	Investing activities:					
Proceeds from disposition of capital assets Cash used for investing activities Financing activities: Borrowings under credit facilities Repayments of credit facility borrowings Debt issuance costs Repayments of other long-term debt Common stock dividends paid Issuance of common stock Payroll tax paid to settle shares forfeited upon vesting of stock Payroll tax paid to settle shares forfeited upon vesting of stock Cash used for financing activities Effect of exchange rate changes on cash and cash equivalents Cash and cash equivalents at beginning of period 152, 363 159 102,000 70,500 70,500 102,000 (100,000) (100,0	Business acquisition		(91,302)		-	
Cash used for investing activities (128,439) (32,962) Financing activities: Borrowings under credit facilities 102,000 70,500 Repayments of credit facility borrowings (100,000) (95,500) Debt issuance costs - (1,210) Repayments of other long-term debt (2,567) (1,747) Common stock dividends paid (10,639) (10,598) Issuance of common stock 1,215 689 Payroll tax paid to settle shares forfeited upon vesting of stock (567) (1,413) Purchase of treasury stock (5,593) (6,600) Cash used for financing activities (16,151) (45,879) Effect of exchange rate changes on cash and cash equivalents 919 (4,092) Increase in cash and cash equivalents 3,381 15,032 Cash and cash equivalents at beginning of period 55,093 40,061	Capital expenditures		(37,390)		(33,121)	
Financing activities: Borrowings under credit facilities 102,000 70,500 Repayments of credit facility borrowings (100,000) (95,500) Debt issuance costs - (1,210) Repayments of other long-term debt (2,567) (1,747) Common stock dividends paid (10,639) (10,598) Issuance of common stock 1,215 689 Payroll tax paid to settle shares forfeited upon vesting of stock (567) (1,413) Purchase of treasury stock (5,593) (6,600) Cash used for financing activities (16,151) (45,879) Effect of exchange rate changes on cash and cash equivalents 919 (4,092) Increase in cash and cash equivalents 3,381 15,032 Cash and cash equivalents at beginning of period 55,093 40,061	Proceeds from disposition of capital assets		253		159	
Borrowings under credit facilities 102,000 70,500 Repayments of credit facility borrowings (100,000) (95,500) Debt issuance costs - (1,210) Repayments of other long-term debt (2,567) (1,747) Common stock dividends paid (10,639) (10,598) Issuance of common stock 1,215 689 Payroll tax paid to settle shares forfeited upon vesting of stock (567) (1,413) Purchase of treasury stock (567) (1,413) Purchase of treasury stock (5,593) (6,600) Cash used for financing activities (16,151) (45,879) Effect of exchange rate changes on cash and cash equivalents 919 (4,092) Increase in cash and cash equivalents 3,381 15,032 Cash and cash equivalents at beginning of period 55,093 40,061	Cash used for investing activities		(128,439)		(32,962)	
Repayments of credit facility borrowings (100,000) (95,500) Debt issuance costs - (1,210) Repayments of other long-term debt (2,567) (1,747) Common stock dividends paid (10,639) (10,598) Issuance of common stock 1,215 689 Payroll tax paid to settle shares forfeited upon vesting of stock (567) (1,413) Purchase of treasury stock (5,593) (6,600) Cash used for financing activities (16,151) (45,879) Effect of exchange rate changes on cash and cash equivalents 919 (4,092) Increase in cash and cash equivalents 3,381 15,032 Cash and cash equivalents at beginning of period 55,093 40,061	Financing activities:					
Debt issuance costs Repayments of other long-term debt Common stock dividends paid Issuance of common stock Payroll tax paid to settle shares forfeited upon vesting of stock Purchase of treasury stock Cash used for financing activities Effect of exchange rate changes on cash and cash equivalents Cash and cash equivalents at beginning of period - (1,210) (2,567) (1,747) (10,639) (10,639) (10,639) (10,699) (567) (1,413) (5593) (6,600) (45,879) (45,879) (40,092) (50) (50) (50) (50) (50) (60) (70)	Borrowings under credit facilities		102,000		70,500	
Debt issuance costs Repayments of other long-term debt Common stock dividends paid Issuance of common stock Payroll tax paid to settle shares forfeited upon vesting of stock Purchase of treasury stock Cash used for financing activities Effect of exchange rate changes on cash and cash equivalents Cash and cash equivalents at beginning of period - (1,210) (2,567) (1,747) (10,639) (10,639) (10,639) (10,699) (567) (1,413) (5593) (6,600) (45,879) (45,879) (40,092) (50) (50) (50) (50) (50) (60) (70)	Repayments of credit facility borrowings		(100,000)		(95,500)	
Common stock dividends paid(10,639)(10,598)Issuance of common stock1,215689Payroll tax paid to settle shares forfeited upon vesting of stock(567)(1,413)Purchase of treasury stock(5,593)(6,600)Cash used for financing activities(16,151)(45,879)Effect of exchange rate changes on cash and cash equivalents919(4,092)Increase in cash and cash equivalents at beginning of period55,09340,061	Debt issuance costs		-		(1,210)	
Common stock dividends paid(10,639)(10,598)Issuance of common stock1,215689Payroll tax paid to settle shares forfeited upon vesting of stock(567)(1,413)Purchase of treasury stock(5,593)(6,600)Cash used for financing activities(16,151)(45,879)Effect of exchange rate changes on cash and cash equivalents919(4,092)Increase in cash and cash equivalents at beginning of period55,09340,061	Repayments of other long-term debt		(2,567)		(1,747)	
Issuance of common stock1,215689Payroll tax paid to settle shares forfeited upon vesting of stock(567)(1,413)Purchase of treasury stock(5,593)(6,600)Cash used for financing activities(16,151)(45,879)Effect of exchange rate changes on cash and cash equivalents919(4,092)Increase in cash and cash equivalents3,38115,032Cash and cash equivalents at beginning of period55,09340,061	Common stock dividends paid				(10,598)	
Payroll tax paid to settle shares forfeited upon vesting of stock Purchase of treasury stock Cash used for financing activities Effect of exchange rate changes on cash and cash equivalents Increase in cash and cash equivalents Cash and cash equivalents at beginning of period (16,151) (45,879) (4,092) (4,092) (4,092) (5,593) (16,151) (45,879) (4,092) (1,413)	Issuance of common stock		1,215		689	
Purchase of treasury stock (5,593) (6,600) Cash used for financing activities (16,151) (45,879) Effect of exchange rate changes on cash and cash equivalents 919 (4,092) Increase in cash and cash equivalents 3,381 15,032 Cash and cash equivalents at beginning of period 55,093 40,061	Payroll tax paid to settle shares forfeited upon vesting of stock				(1,413)	
Cash used for financing activities (16,151) (45,879) Effect of exchange rate changes on cash and cash equivalents 919 (4,092) Increase in cash and cash equivalents 3,381 15,032 Cash and cash equivalents at beginning of period 55,093 40,061	Purchase of treasury stock					
Effect of exchange rate changes on cash and cash equivalents919(4,092)Increase in cash and cash equivalents3,38115,032Cash and cash equivalents at beginning of period55,09340,061	•		•		_	
Increase in cash and cash equivalents 3,381 15,032 Cash and cash equivalents at beginning of period 55,093 40,061						
Cash and cash equivalents at beginning of period 55,093 40,061					_	
	·					
	Cash and cash equivalents at end of period	\$	58,474	\$	55,093	

QUANEX BUILDING PRODUCTS CORPORATION FREE CASH FLOW AND NET DEBT RECONCILIATION

(In thousands) (Unaudited)

The following table reconciles the Company's calculation of Free Cash Flow, a non-GAAP measure, to its most directly comparable GAAP measure. The Company defines Free Cash Flow as cash provided by operating activities less capital expenditures.

	Three Months Ende	d October 31,	Twelve Months Ende	ed October, 31		
	2023	2022	2023	2022		
Cash provided by operating activities	\$44,493	\$48,111	\$147,052	\$97,965		
Capital expenditures	(14,940)	(13,633)	(37,390)	(33,121)		
Free Cash Flow	\$29,553	\$34,478	\$109,662	\$64,844		

The following table reconciles the Company's Net Debt which is defined as total debt principal of the Company plus finance lease obligations minus cash.

	As of October 31,					
	2023	2022				
Revolving credit facility	\$15,000	\$13,000				
Finance lease obligations (1)	55,000	19,202				
Total debt ⁽²⁾	70,000	32,202				
Less: Cash and cash equivalents	58,474	55,093				
Net Debt	\$11,526	(\$22,891)				

⁽¹⁾ Includes \$51.5 million and \$17.7 million in real estate lease liabilities considered finance leases under U.S. GAAP as of October 31, 2023 and October 31, 2022, respectively.

⁽²⁾ Excludes outstanding letters of credit.

QUANEX BUILDING PRODUCTS CORPORATION NON-GAAP FINANCIAL MEASURE DISCLOSURE LAST TWELVE MONTHS ADJUSTED EBITDA RECONCILIATION

(In thousands, except per share data) (Unaudited)

Reconciliation of Last Twelve Months Adjusted EBITDA		Three Months Ended October 31, 2023		Three Months Ended July 31, 2023		Three Months Ended April 30, 2023																																							Total
	F	teconciliation		Reconciliation	Reconciliation		Reconciliation			Reconciliation																																			
Net income as reported	\$	27,382	\$	31,698	\$	21,512		1,909	\$	82,501																																			
Income tax expense		4,442		4,099		5,551		453		14,545																																			
Other, net		6,110		(402)		29		(218)		5,519																																			
Interest expense		1,565		2,068		2,244		2,259		8,136																																			
Depreciation and amortization		11,194		10,596		10,456		10,620		42,866																																			
EBITDA		50,693		48,059		39,792		15,023		153,567																																			
Cost of sales (1)		(35)		-		48		-		13																																			
Selling, general and administrative (1),(2)		109		395		63		5,448		6,015																																			
Adjusted EBITDA	\$	50,767	\$	48,454	\$	39,903	-	20,471	\$	159,595																																			

⁽¹⁾ Loss on damage to manufacturing facilities caused by weather. (2) Transaction and advisory fees.

QUANEX BUILDING PRODUCTS CORPORATION NON-GAAP FINANCIAL MEASURE DISCLOSURE

(In thousands, except per share data) (Unaudited)

	Three N	lonths En	ded		Three Months Ended Twelve Months End					nded	Twelve Months Ended							
Reconciliation of Adjusted Net Income and Adjusted EPS	Octob	er 31, 202	23			October	31, 2022			October:	31. 202	23			October 31, 2022			
	Net		iluted			Net	Diluted			Net		iluted		-	Net		uted	
	Income		EPS		li	ncome	EPS			Income		EPS		- 1	ncome	E	PS	
Net income as reported	\$ 27,382	\$	0.83		\$	24,667	\$ 0.	75	_	\$ 82,501	\$	2.50		\$	88,336	\$	2.66	
Net income reconciling items from below	3,853		0.12			290	\$ -		_	8,401	\$	0.25			581	\$	0.02	
Adjusted net income and adjusted EPS	\$ 31,233	\$	0.95		\$	24,957	\$ 0.	75	-	\$ 90,902	\$	2.75		\$	88,917	\$	2.68	
	Three N	lonths En	ded			Three Mon	nths Ended		ſ	Twelve Mor	nths Er	nded			Twelve Mo	nths End	led	
Reconciliation of Adjusted EBITDA	Octob	er 31, 202	23			October	31, 2022			October:	31, 202	23			October	31, 2022		
	Reconciliatio	1			Reco	nciliation				Reconciliation		•		Rec	onciliation		•	
Net income as reported	\$ 27,382				\$	24,667			-	\$ 82,501				\$	88,336			
Income tax expense	4,442					3,329				14,545					21,427			
Other, net	6,110)				(136)				5,519					(1,041)			
Interest expense	1,565					710				8,136					2,559			
Depreciation and amortization	11,194					9,555			_	42,866					40,109			
EBITDA	50,693					38,125				153,567					151,390			
EBITDA reconciling items from below	74					564			_	6,028					1,114			
Adjusted EBITDA	\$ 50,767	_			\$	38,689				\$ 159,595				\$	152,504			
	Three N	lonths En	ded			Three Mon	nths Ended		Twelve Months Ended					Twelve Months Ended				
Reconciling Items		er 31, 202				October				October:				October 31, 2022				
	Income	Rec	onciling		li	ncome	Reconcili	ng		Income	Rec	conciling			ncome	Reco	nciling	
	Statement		tems			tement	Items		_	Statement		Items			atement		ems	
Net sales	\$ 295,492		-		\$	307,532	\$ -			\$ 1,130,583	\$	-		\$	1,221,502	\$	-	
Cost of sales	215,473		35	(1)		240,073	-			853,059		(13)	(1)		953,004		-	
Selling, general and administrative	29,326		(109)	(1),(2)		29,334		<u>64)</u> (2	2)	123,957		(6,015)	(1),(2)		117,108		(1,114) (2)	
EBITDA	50,693		74			38,125	5	64		153,567		6,028			151,390		1,114	
Depreciation and amortization	11,194					9,555			_	42,866					40,109			
Operating income	39,499		74			28,570	5	64		110,701		6,028			111,281		1,114	
Interest expense	(1,569					(710)	-			(8,136)					(2,559)		-	
Other, net	(6,110		5,232	(3)		136		<u>22)</u> (3 42	3) _	(5,519)		5,196	(3)		1,041		(386) (3) 728	
Income before income taxes	31,824		5,306	(4)		27,996			41	97,046		11,224	(4)		109,763			
Income tax expense Net income	\$ 27.382		(1,455) 3.851	(4)	Ś	(3,329)		52) (4 90		(14,545) \$ 82,501	Ś	(2,823) 8,401	(4)	Ś	(21,427) 88.336	Ś	(147) (4) 581	
wet income			3,851		ş		3 2	90	-	Ç 02,501	ې	0,401				ş	201	
Diluted earnings per share	\$ 0.83	}			\$	0.75				\$ 2.50				\$	2.66			

⁽¹⁾ Loss on damage to manufacturing facilities caused by weather.

⁽²⁾ Transaction and advisory fees.
(3) Foreign currency translation losses (gains) and pension settlement expense.
(4)Tax impact of net income reconciling items.

QUANEX BUILDING PRODUCTS CORPORATION SELECTED SEGMENT DATA

(In thousands) (Unaudited)

This table provides gross margin, operating (loss) income, EBITDA, and Adjusted EBITDA by reportable segment. Non-operating expense and income tax expense are not allocated to the reportable segments.

allocated to the reportable segments.					NA	Cabinet	Una	llocated		
	NA F	enestration	EU Fe	enestration	Com	ponents	Corp	& Other		Total
Three months ended October 31, 2023										
Net sales	\$	180,446	\$	64,170	\$	51,868	\$	(992)	\$	295,492
Cost of sales		135,490		39,070		41,488		(575)		215,473
Gross Margin		44,956		25,100		10,380		(417)		80,019
Gross Margin %		24.9%		39.1%		20.0%				27.1%
Selling, general and administrative		15,272		8,354		5,135		565		29,326
Depreciation and amortization		5,211		2,714		3,220		(1.021)		11,194
Operating income (loss)		24,473		14,032		2,025		(1,031)		39,499
Depreciation and amortization EBITDA		5,211 29,684		2,714 16,746		3,220 5,245		(982)		11,194 50,693
Loss on damage to manufacturing facilities (Cost of sales)		(35)		10,740		3,243		(362)		(35)
Loss on damage to manufacturing facilities (CG&A)		(33)		_		(131)		_		(131)
Transaction and advisory fees		_		_		- (151)		240		240
Adjusted EBITDA	\$	29,649	\$	16,746	\$	5,114	\$	(742)	\$	50,767
Adjusted EBITDA Margin %	<u> </u>	16.4%		26.1%		9.9%		χ. :=/		17.2%
Three months ended October 31, 2022										
Net sales	\$	178,175	\$	62,104	\$	67,993	\$	(740)	\$	307,532
Cost of sales		141,395		42,121		56,904		(347)		240,073
Gross Margin		36,780		19,983		11,089		(393)		67,459
Gross Margin %		20.6%		32.2%		16.3%				21.9%
Selling, general and administrative		15,636		7,686		6,111		(99)		29,334
Depreciation and amortization		4,032		2,256		3,177		90		9,555
Operating income (loss)		17,112		10,041		1,801		(384)		28,570
Depreciation and amortization		4,032		2,256		3,177		90		9,555
EBITDA		21,144		12,297		4,978		(294)		38,125
Transaction and advisory fees		-		-		-		564		564
Adjusted EBITDA	\$	21,144	\$	12,297	\$	4,978	\$	270	\$	38,689
Adjusted EBITDA Margin %		11.9%		19.8%		7.3%				12.6%
Twelve months ended October 31, 2023										
Net sales	\$	667,482	\$	250,774	\$	215,445	\$	(3,118)	\$	1,130,583
Cost of sales		517,805		158,491		178,210		(1,447)		853,059
Gross Margin		149,677		92,283		37,235		(1,671)		277,524
Gross Margin %		22.4%		36.8%		17.3%				24.5%
Selling, general and administrative		56,979		32,350		21,074		13,554		123,957
Depreciation and amortization		20,539		9,849		12,208		270		42,866
Operating income (loss)		72,159		50,084		3,953		(15,495)		110,701
Depreciation and amortization		20,539		9,849		12,208		270		42,866
EBITDA		92,698		59,933		16,161		(15,225)		153,567
Loss on damage to manufacturing facilities (Cost of sales)		-		-		13 69		-		13
Loss on damage to manufacturing facilities (SG&A) Transaction and advisory fees		-		-		09		5,946		69 5,946
Adjusted EBITDA	\$	92,698	\$	59,933	\$	16,243	\$	(9,279)	\$	159,595
Adjusted EBITDA Margin %	<u>, , , , , , , , , , , , , , , , , , , </u>	13.9%	Ţ	23.9%	Ţ	7.5%	Ţ	(3,273)	Ţ	14.1%
Twelve months ended October 31, 2022										
Net sales	\$	687,458	\$	262,058	\$	275,704	\$	(3,718)	\$	1,221,502
Cost of sales	7	537,900	7	180,268	7	236,695	7	(1,859)	Y	953,004
Gross Margin		149,558		81,790		39,009		(1,859)		268,498
Gross Margin %		21.8%		31.2%		14.1%		(2)000)		22.0%
Selling, general and administrative		58,735		31,846		21,934		4,593		117,108
Depreciation and amortization		16,253		9,674		13,830		352		40,109
Operating income (loss)	-	74,570		40,270		3,245		(6,804)		111,281
Depreciation and amortization		16,253		9,674		13,830		352		40,109
EBITDA	-	90,823		49,944		17,075		(6,452)		151,390
Transaction and advisory fees		-		-		-		1,114		1,114
Adjusted EBITDA	\$	90,823	\$	49,944	\$	17,075	\$	(5,338)	\$	152,504
Adjusted EBITDA Margin %		13.2%		19.1%		6.2%				12.5%

QUANEX BUILDING PRODUCTS CORPORATION SALES ANALYSIS

(In thousands) (Unaudited)

	Three Months Ended October 31,					Twelve Months Ended October, 31						
	<u>2023</u>			<u>2022</u>		<u>2023</u>		<u>2022</u>				
NA Fenestration: (1)												
United States - fenestration	\$	138,783	\$	162,147	\$	518,396	\$	609,572				
International - fenestration		8,081		4,954		30,100		35,906				
United States - non-fenestration		29,267		6,922		103,090		29,039				
International - non-fenestration		4,315		4,152		15,896		12,941				
	\$	180,446	\$	178,175	\$	667,482	\$	687,458				
EU Fenestration: (2)												
International - fenestration	\$	49,862	\$	46,329	\$	191,871	\$	194,854				
International - non-fenestration		14,308		15,775		58,903		67,204				
	\$	64,170	\$	62,104	\$	250,774	\$	262,058				
NA Cabinet Components:												
United States - fenestration	\$	4,286	\$	4,408	\$	16,899	\$	17,696				
United States - non-fenestration		47,092		62,818		195,866		254,726				
International - non-fenestration		490		767		2,680		3,282				
	\$	51,868	\$	67,993	\$	215,445	\$	275,704				
Unallocated Corporate & Other:												
Eliminations	\$	(992)	\$	(740)	\$	(3,118)	\$	(3,718)				
	\$	(992)	\$	(740)	\$	(3,118)	\$	(3,718)				
Net Sales	\$	295,492	\$	307,532	\$	1,130,583	\$	1,221,502				

⁽¹⁾ Includes the net sales from the acquisition of LMI of \$21.4 million and \$75.6 million for the three and twelve months ended October 31, 2023, respectively.

(2) Reflects an increase of \$4.5 million and a reduction of \$4.1 million in revenue associated with foreign currency exchange rate impacts for the three and twelve months ended October 31, 2023, respectively.